Navigation Links
UConn chemists find secret to increasing luminescence efficiency of carbon nanotubes
Date:3/6/2009

STORRS, Conn. - Chemists at the University of Connecticut have found a way to greatly increase the luminescence efficiency of single-walled carbon nanotubes, a discovery that could have significant applications in medical imaging and other areas.

Increasing the luminescence efficiency of carbon nanotubes may someday make it possible for doctors to inject patients with microscopic nanotubes to detect tumors, arterial blockages and other internal problems. Rather than relying on potentially harmful x-rays or the use of radioactive dyes, physicians could simply scan patients with an infrared light that would capture a very sharp resolution of the luminescence of the nanotubes in problem areas.

UConn's process of increasing the luminescence efficiency of single-walled carbon nanotubes will be featured in Science magazine on Friday, March 6, 2009. The research was performed in the Nanomaterials Optoelectronics Laboratory at the Institute of Materials Science at the University of Connecticut, in Storrs, CT. A patent for the process is pending.

University of Connecticut Chemist Fotios Papadimitrakopoulos describes the discovery as a major breakthrough and one of the most significant discoveries in his 10 years of working with single-walled carbon nanotubes. Assisting Papadimitrakopoulos with the research were Polymer Program graduate student Sang-Yong Ju (now a researcher at Cornell University) and William P. Kopcha, a former Chemistry undergraduate assistant in the College of Liberal Arts and Sciences who is now a first-year graduate student at UConn.

Although carbon is used in many diverse applications, scientists have long been stymied by the element's limited ability to emit light. The best scientists have been able to do with solution-suspended carbon nanotubes was to raise their luminescence efficiency to about one-half of one percent, which is extremely low compared to other materials, such as quantum dots and quant
'/>"/>

Contact: Colin Poitras
colin.poitras@uconn.edu
860-486-4656
University of Connecticut
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Clemson chemists discover new way antioxidants fight debilitating diseases
2. Chemists get grip on slippery lipids
3. Good earth: Brown chemists show origin of soil-scented geosmin
4. Team of chemists receives $5 million grant to develop enzyme mimics
5. Biochemists reveal details of mysterious bacterial microcompartments
6. Biologists are from Mars, chemists are from Venus?
7. Glowing films developed by UC San Diego chemists reveal traces of explosives
8. NIST chemists get scoop on crude oil from pig manure
9. Chemists make beds with soft landings
10. Biochemists manipulate fruit flavor enzymes
11. Smoke smudges Mexico Citys air, chemists identify sources
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Surety Leads Web Symposium to Address Data Integrity Issues in Bio-Sciences Industry 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 2ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 3ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 4AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 2AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 3